At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Alteplase (iv t-PA)drug
Likely dose
Alteplase (iv t-PA) 0.9 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of Intravenous Thrombolysis for Wake-up Stroke
The University of Texas Health Science Center, Houston·interventional·Posted Aug 17, 2010·Updated Nov 25, 2014
In Brief
A Phase 2 clinical trial evaluating Alteplase (iv t-PA) for Ischemic Stroke. Completed, enrolled 40 participants across 3 sites.
Detailed Summary
The purpose is to demonstrate the safety of intravenous tissue plasminogen activator (IV t-PA) in ischemic stroke patients who present to the emergency department (ED) after awakening with the symptoms of suspected ischemic stroke.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedAug 2010
Primary CompletionOct 2013
Study CompletionJan 2014
TodayJul 2026
First PostedAug 17, 2010
Enrollment StartJul 1, 2010
Primary CompletionOct 1, 2013
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.9 years ago
Interventions
Alteplase (iv t-PA)drug
0.9 mg/kg (maximum of 90 mg) IV t-PA will be administered with 10% bolus given over 1 minute, the rest given as an infusion over the remaining hour.